Cargando…
Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb)
BACKGROUND: Bevacizumab-awwb (MVASI(®)) was the first U.S. Food and Drug Administration-approved biosimilar to Avastin(®) (reference product [RP]) for the treatment of several different types of cancers, including metastatic colorectal cancer (mCRC), an indication approved based on extrapolation. OB...
Autores principales: | Jin, Ran, Ogbomo, Adesuwa S., Accortt, Neil A., Lal, Lincy S., Bishi, Geetanjali, Sandschafer, Darcie, Goldschmidt, Jerome H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288425/ https://www.ncbi.nlm.nih.gov/pubmed/37360769 http://dx.doi.org/10.1177/17588359231182386 |
Ejemplares similares
-
Clinical and treatment characteristics of patients treated with the first therapeutic oncology biosimilars bevacizumab-awwb and trastuzumab-anns in the US
por: Jin, Ran, et al.
Publicado: (2021) -
The Totality of Evidence and Use of ABP 215, a Biosimilar to Bevacizumab
por: Goldschmidt, Jerome, et al.
Publicado: (2020) -
Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation
por: Ratra, Dhanashree, et al.
Publicado: (2021) -
SB8: A Bevacizumab Biosimilar
por: Syed, Yahiya Y.
Publicado: (2020) -
Development of the Drug Product Formulation of the Bevacizumab Biosimilar PF-06439535 (Bevacizumab-bvzr)
por: Ingram, Rebecca L., et al.
Publicado: (2023)